Q1 Earnings Forecast for MNMD Issued By Leerink Partnrs

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) – Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Mind Medicine (MindMed) in a report released on Sunday, April 13th. Leerink Partnrs analyst M. Goodman forecasts that the company will earn ($0.35) per share for the quarter. The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($1.35) per share. Leerink Partnrs also issued estimates for Mind Medicine (MindMed)’s Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.47) EPS and FY2028 earnings at ($1.65) EPS.

Mind Medicine (MindMed) (NASDAQ:MNMD) last released its earnings results on Thursday, March 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.08). During the same period in the previous year, the firm posted ($0.59) earnings per share.

A number of other equities analysts have also weighed in on the stock. Evercore ISI assumed coverage on shares of Mind Medicine (MindMed) in a research report on Tuesday, January 28th. They set an “outperform” rating and a $23.00 target price for the company. Robert W. Baird dropped their price objective on shares of Mind Medicine (MindMed) from $27.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, March 7th. Chardan Capital assumed coverage on Mind Medicine (MindMed) in a research report on Friday, December 20th. They set a “buy” rating and a $20.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $55.00 target price on shares of Mind Medicine (MindMed) in a research report on Friday, March 7th. Ten research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $25.11.

Mind Medicine (MindMed) Trading Up 5.7 %

Shares of MNMD opened at $5.77 on Wednesday. The firm has a market cap of $434.87 million, a P/E ratio of -2.55 and a beta of 2.54. The company has a debt-to-equity ratio of 0.09, a current ratio of 9.00 and a quick ratio of 9.00. Mind Medicine has a 1 year low of $4.70 and a 1 year high of $10.44. The company has a 50 day simple moving average of $6.59 and a two-hundred day simple moving average of $6.89.

Insider Buying and Selling at Mind Medicine (MindMed)

In related news, CEO Robert Barrow sold 21,208 shares of the stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $6.74, for a total value of $142,941.92. Following the sale, the chief executive officer now directly owns 856,556 shares of the company’s stock, valued at $5,773,187.44. This represents a 2.42 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Daniel Karlin sold 6,836 shares of the firm’s stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total transaction of $46,074.64. Following the completion of the sale, the insider now directly owns 446,177 shares of the company’s stock, valued at approximately $3,007,232.98. The trade was a 1.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,391 shares of company stock worth $204,835 over the last ninety days. Company insiders own 2.26% of the company’s stock.

Institutional Investors Weigh In On Mind Medicine (MindMed)

A number of institutional investors and hedge funds have recently modified their holdings of the business. State Street Corp increased its stake in Mind Medicine (MindMed) by 0.5% in the third quarter. State Street Corp now owns 1,814,829 shares of the company’s stock worth $10,326,000 after purchasing an additional 9,782 shares during the period. Wellington Management Group LLP increased its stake in Mind Medicine (MindMed) by 142.6% in the 3rd quarter. Wellington Management Group LLP now owns 185,722 shares of the company’s stock worth $1,057,000 after buying an additional 109,152 shares during the period. XTX Topco Ltd bought a new stake in Mind Medicine (MindMed) during the 3rd quarter valued at about $337,000. Barclays PLC boosted its position in Mind Medicine (MindMed) by 203.6% in the 3rd quarter. Barclays PLC now owns 136,098 shares of the company’s stock valued at $775,000 after buying an additional 91,271 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of Mind Medicine (MindMed) by 10.8% during the third quarter. Geode Capital Management LLC now owns 1,677,702 shares of the company’s stock worth $9,548,000 after acquiring an additional 162,933 shares during the period. 27.91% of the stock is owned by institutional investors.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.